AR099602A1 - DERIVADO DE PIRAZOL AMIDA CON ACTIVIDAD MODULADORA DE RORg - Google Patents

DERIVADO DE PIRAZOL AMIDA CON ACTIVIDAD MODULADORA DE RORg

Info

Publication number
AR099602A1
AR099602A1 ARP150100609A ARP150100609A AR099602A1 AR 099602 A1 AR099602 A1 AR 099602A1 AR P150100609 A ARP150100609 A AR P150100609A AR P150100609 A ARP150100609 A AR P150100609A AR 099602 A1 AR099602 A1 AR 099602A1
Authority
AR
Argentina
Prior art keywords
groups
group
substituted
alkyl
group substituted
Prior art date
Application number
ARP150100609A
Other languages
English (en)
Original Assignee
Teijin Pharma Ltd
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Amgen Inc filed Critical Teijin Pharma Ltd
Publication of AR099602A1 publication Critical patent/AR099602A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Derivado de pirazol amida que tiene una función de inhibición de la actividad de RORg. Además, una composición farmacéutica que comprende el compuesto, un uso del compuesto para tratar o prevenir enfermedades autoinmunes, enfermedades inflamatorias, enfermedades metabólicas o enfermedades cancerosas. Reivindicación 1: Un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: R¹ se selecciona de F, Cl, Br, un grupo alquilo C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᵃ y un grupo cicloalquilo C₃₋₈ sustituido por 0, 1, 2 ó 3 grupos Rᵃ; Y se selecciona de un grupo cicloalquilo C₄₋₆, un grupo bicicloalquilo C₆₋₉ y un grupo espiroalquilo C₆₋₉, todos los cuales están sustituidos por un grupo R², 0 ó 1 grupos R⁶ y 0, 1, 2 ó 3 grupos R⁷; R² se selecciona de -OH, -CO₂H, -SO₃H, -CONH₂, -SO₂NH₂, un grupo (alcoxi C₁₋₆)carbonilo sustituido por 0, 1, 2 ó 3 grupos Rᶜ, un grupo (alquil C₁₋₆)aminocarbonilo sustituido por 0, 1, 2 ó 3 grupos Rᶜ, un grupo alquilsulfonilo C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᶜ, un grupo alquilaminosulfonilo C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᶜ, un grupo (hidroxicarbonil)(alquilo C₁₋₃) sustituido por 0, 1, 2 ó 3 grupos Rᶜ, un grupo (alcoxi C₁₋₆)carbonil(alquilo C₁₋₃) sustituido por 0, 1, 2 ó 3 grupos Rᶜ, un grupo (alquil C₁₋₆)sulfonil(alquilo C₁₋₃) sustituido por 0, 1, 2 ó 3 grupos Rᶜ y un grupo (alquenil C₂₋₆)(alquilo C₁₋₃) sustituido por 0, 1, 2 ó 3 grupos Rᶜ; R⁶ y R⁷ se seleccionan en forma independiente de H, F, -OH, -NH₂, -CN, un grupo alquilo C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᵇ y un grupo alcoxi C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᵇ; R³ se selecciona de H, F, Cl, -CH₃ y -CF₃; R⁴ se selecciona de un grupo alquilo C₁₋₆ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵉ, un grupo (alquenil C₂₋₆)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵉ, un grupo (alquinil C₂₋₆)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵉ, un grupo (alcoxi C₁₋₆)(alquilo C₂₋₄) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵉ, un grupo (aril C₆₋₁₀)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᶠ, un grupo (heteroarilo de 5 a 10 miembros)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᶠ, un grupo cicloalquilo C₃₋₈ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo cicloalquenilo C₃₋₈ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo (cicloalquil C₃₋₈)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo (cicloalquenil C₃₋₈)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo heterocicloalquilo de 3 a 8 miembros sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ y un grupo (heterocicloalquilo de 3 a 8 miembros)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo espiroalquilo C₆₋₉ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo (espiroalquil C₆₋₉)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo espiroheteroalquilo C₆₋₉ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo bicicloalquilo C₅₋₉ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo (bicicloalquil C₅₋₉)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo heterobicicloalquilo C₆₋₉ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, y un grupo (heterobicicloalquil C₆₋₉)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ; R⁵ se selecciona de un grupo arilo C₆₋₁₀ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rⁱ, un grupo heteroarilo de 5 a 10 miembros sustituido por 0, 1, 2, 3 ó 4 grupos Rⁱ, un grupo cicloalquilo C₃₋₈ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rʲ, un grupo cicloalquenilo C₃₋₈ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rʲ y un grupo heterocicloalquilo de 3 a 8 miembros sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rʲ; R⁸ y R⁹ se seleccionan en forma independiente de H, F, -OH, -NH₂, un grupo alquilo C₁₋₃ sustituido por 0, 1, 2 ó 3 grupos Rʰ, y un grupo alcoxi C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rʰ; o R⁸ y R⁹ juntos forman un grupo oxo o un grupo tioxo; R¹² es H; o R⁴ y R¹² juntos son -CRᵐRᵐ-CR¹³R¹⁴-CRᵐRᵐ- o -CR¹³R¹⁴-CRᵐRᵐ-CRᵐRᵐ- para formar un anillo pirrolidina; R¹³ se selecciona de H, un grupo alquilo C₁₋₆ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵉ, un grupo arilo C₆₋₁₀ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᶠ, un grupo ariloxi C₆₋₁₀ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᶠ, un grupo (alquenil C₂₋₆)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵉ, un grupo (alquinil C₂₋₆)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵉ, un grupo (alcoxi C₁₋₆)(alquilo C₂₋₄) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵉ, un grupo (aril C₆₋₁₀)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᶠ, un grupo (heteroarilo de 5 a 10 miembros)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᶠ, un grupo cicloalquilo C₃₋₈ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo cicloalquenilo C₃₋₈ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo (cicloalquil C₃₋₈)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo (cicloalquenil C₃₋₈)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo heterocicloalquilo de 3 a 8 miembros sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ y un grupo (heterocicloalquilo de 3 a 8 miembros)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo espiroalquilo C₆₋₉ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo (espiroalquil C₆₋₉)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo espiroheteroalquilo C₆₋₉ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo bicicloalquilo C₆₋₉ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo (bicicloalquil C₅₋₉)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un grupo heterobicicloalquilo C₆₋₉ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, y un grupo (heterobicicloalquil C₆₋₉)(alquilo C₁₋₃) sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ; R¹⁴ se selecciona en forma independiente de H y un grupo alquilo C₁₋₆ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵉ; o R¹³ y R¹⁴ juntos forman un anillo cicloalcano C₃₋₈ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, un anillo cicloalqueno C₃₋₈ sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ, o un anillo heterocicloalcano de 3 a 8 miembros sustituido por 0, 1, 2, 3, 4 ó 5 grupos Rᵍ; Rᵐ se selecciona en forma independiente de H, F, Cl, -CH₃ y -CF₃; Rᵍ y Rʲ se seleccionan en forma independiente de F, Cl, un grupo alquilo C₁₋₆, -OH, -CN, -NH₂, -NO₂, -CO₂H, un grupo alcoxi C₁₋₆, un grupo mono(alquil C₁₋₆)amino, un grupo di(alquil C₁₋₆)amino, -CF₃, un grupo alquileno C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rˡ, un grupo alquenileno C₂₋₆ sustituido por 0, 1, 2 ó 3 grupos Rˡ y un grupo oxo; Rᶠ y Rⁱ se seleccionan en forma independiente de F, Cl, Br, -OH, -CN, -NO₂, -CO₂H, un grupo alquilo C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo alquenilo C₂₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo alquinilo C₂₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo cicloalquilo C₃₋₈ sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo alcoxi C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo cicloalquiloxi C₃₋₈ sustituido por 0, 1, 2 ó 3 grupos Rᵏ, -SH, un grupo alquiltio C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo cicloalquiltio C₃₋₈ sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo (alquil C₁₋₆)carbonilo sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo (alcoxi C₁₋₆)carbonilo sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo (alquil C₁₋₆)aminocarbonilo sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo heterocicloalquilo de 3 a 8 miembros sustituido por 0, 1, 2 ó 3 grupos Rᵏ, un grupo alquilsulfonilo C₁₋₆ sustituido por 0, 1, 2 ó 3 grupos Rᵏ, -NH₂, un grupo mono(alquil C₁₋₆)amino sustituido por 0, 1, 2 ó 3 grupos Rᵏ y un grupo di(alquil C₁₋₆)amino sustituido por 0, 1, 2 ó 3 grupos Rᵏ; y Rᵃ, Rᵇ, Rᶜ, Rᵉ, Rʰ, Rᵏ y Rˡ se seleccionan en forma independiente de F, un grupo alquilo C₁₋₄, -OH, -CN, -NO₂, -NH₂, -CO₂H, un grupo alcoxi C₁₋₆, un grupo mono(alquil C₁₋₆)amino, un grupo di(alquil C₁₋₆)amino, -CF₃ y un grupo oxo.
ARP150100609A 2014-02-28 2015-02-27 DERIVADO DE PIRAZOL AMIDA CON ACTIVIDAD MODULADORA DE RORg AR099602A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014039880 2014-02-28

Publications (1)

Publication Number Publication Date
AR099602A1 true AR099602A1 (es) 2016-08-03

Family

ID=52779995

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100609A AR099602A1 (es) 2014-02-28 2015-02-27 DERIVADO DE PIRAZOL AMIDA CON ACTIVIDAD MODULADORA DE RORg

Country Status (27)

Country Link
US (1) US9365522B2 (es)
EP (1) EP3110810B1 (es)
JP (1) JP6211207B2 (es)
KR (1) KR102309352B1 (es)
CN (1) CN106459003B (es)
AR (1) AR099602A1 (es)
AU (1) AU2015223742C1 (es)
BR (1) BR112016019592B1 (es)
CA (1) CA2940696C (es)
CY (1) CY1120452T1 (es)
DK (1) DK3110810T3 (es)
ES (1) ES2673279T3 (es)
HR (1) HRP20180750T1 (es)
HU (1) HUE038645T2 (es)
IL (1) IL247426B (es)
LT (1) LT3110810T (es)
MX (1) MX2016011072A (es)
PH (1) PH12016501702A1 (es)
PL (1) PL3110810T3 (es)
PT (1) PT3110810T (es)
RS (1) RS57575B1 (es)
RU (1) RU2658827C2 (es)
SG (1) SG11201607045SA (es)
SI (1) SI3110810T1 (es)
TW (1) TWI659019B (es)
UY (1) UY36014A (es)
WO (1) WO2015129926A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
RU2742771C2 (ru) 2016-08-31 2021-02-10 Цзянсу Хэнжуй Медицин Ко., Лтд. Производное оксопиколинамида, способ его получения и его фармацевтическое применение
AU2017376580B2 (en) * 2016-12-15 2020-08-13 F. Hoffmann-La Roche Ag Process for preparing BTK inhibitors
WO2018115984A1 (en) 2016-12-19 2018-06-28 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation
JP2020059651A (ja) * 2016-12-26 2020-04-16 科研製薬株式会社 ピラゾール誘導体及びそれを含有する医薬
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN112566901A (zh) 2018-06-18 2021-03-26 詹森药业有限公司 作为RORγt的调节剂的苯基取代的吡唑类
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt
JP2021529161A (ja) * 2018-06-18 2021-10-28 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレーターとしてのピリジニルピラゾール
US11345666B2 (en) 2018-06-18 2022-05-31 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
CN108752185A (zh) * 2018-07-17 2018-11-06 成都道合尔医药技术有限公司 一种1-氟-环戊甲酸的合成方法
WO2020037109A1 (en) * 2018-08-17 2020-02-20 Dow Agrosciences Llc Processes for fluorination
GB201901559D0 (en) 2019-02-05 2019-03-27 Syngenta Crop Protection Ag Herbicidal compositions
CN112552158B (zh) * 2020-12-09 2023-05-19 南京工业大学 一种含酮羧酸结构的高吸收铬鞣助剂的制备及应用
CN115108980B (zh) * 2022-06-22 2023-06-16 济南大学 一种2-甲基喹啉类化合物的4号位酰基化衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
PL2729445T3 (pl) 2011-07-04 2016-04-29 Rottapharm Biotech Srl Cykliczne pochodne aminowe jako antagoniści receptora EP4
EP2738170B1 (en) * 2011-07-29 2017-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP5918859B2 (ja) * 2011-12-02 2016-05-18 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＡＲに関連するオーファン受容体−ガンマ（ＲＯＲγ、ＮＲ１Ｆ３）活性の調整剤としての、慢性の炎症性疾患および自己免疫性疾患を治療するためのピロロカルボキサミド
JO3215B1 (ar) * 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy

Also Published As

Publication number Publication date
SI3110810T1 (sl) 2018-11-30
UY36014A (es) 2015-09-30
DK3110810T3 (en) 2018-07-23
EP3110810B1 (en) 2018-05-02
RS57575B1 (sr) 2018-11-30
IL247426A0 (en) 2016-11-30
PL3110810T3 (pl) 2018-12-31
CN106459003A (zh) 2017-02-22
BR112016019592A2 (es) 2017-08-15
HUE038645T2 (hu) 2018-11-28
ES2673279T3 (es) 2018-06-21
JP2017510560A (ja) 2017-04-13
AU2015223742A1 (en) 2016-09-01
AU2015223742C1 (en) 2019-02-21
CA2940696A1 (en) 2015-09-03
CA2940696C (en) 2022-04-26
PT3110810T (pt) 2018-07-31
WO2015129926A1 (en) 2015-09-03
JP6211207B2 (ja) 2017-10-11
MX2016011072A (es) 2016-11-30
NZ723766A (en) 2022-03-25
RU2016138364A (ru) 2018-03-30
BR112016019592B1 (pt) 2021-03-09
BR112016019592A8 (pt) 2018-01-02
RU2016138364A3 (es) 2018-03-30
HRP20180750T1 (hr) 2018-06-15
PH12016501702B1 (en) 2016-10-03
AU2015223742B2 (en) 2018-11-15
KR102309352B1 (ko) 2021-10-05
CN106459003B (zh) 2019-06-21
TW201623236A (zh) 2016-07-01
TWI659019B (zh) 2019-05-11
SG11201607045SA (en) 2016-09-29
EP3110810A1 (en) 2017-01-04
RU2658827C2 (ru) 2018-06-25
US20150266824A1 (en) 2015-09-24
PH12016501702A1 (en) 2016-10-03
US9365522B2 (en) 2016-06-14
IL247426B (en) 2020-01-30
CY1120452T1 (el) 2019-07-10
KR20160141721A (ko) 2016-12-09
LT3110810T (lt) 2018-07-10

Similar Documents

Publication Publication Date Title
AR099602A1 (es) DERIVADO DE PIRAZOL AMIDA CON ACTIVIDAD MODULADORA DE RORg
AR119454A2 (es) COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO
AR119761A2 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR109595A1 (es) Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
AR090862A1 (es) Compuestos de tetrazolinona y su uso para combatir plagas
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
DOP2017000127A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
AR097862A1 (es) Inhibidores de tirosina quinasa de bruton
AR095034A1 (es) El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR094300A1 (es) Derivados de quinolonas
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
PE20190500A1 (es) Moduladores del receptor nmda spiro-lactam y uso de los mismos
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR092628A1 (es) Piridinonas biciclicas
AR089284A1 (es) Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
PE20190504A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
AR110351A1 (es) COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa
AR102972A1 (es) Compuestos de dihidropirimidin-2-ona y su uso médico
AR101638A1 (es) Combinaciones de inhibidores de la recaptación de serotonina-norepinefrina (irsn) y ligandos del receptores sigma

Legal Events

Date Code Title Description
FB Suspension of granting procedure